This was the founding year for the AASCC and over the course of the past 12 months the group has set the foundations for what we hope will be a long and successful future. The Consortia has established a core and growing membership of growing companies in the field of Alzheimer’s, defined its core mission and elected co-chairs to work with Jim Hendrix of the Alzheimer’s Association in developing the group.

For those of you not familiar with the AASCC, we encourage you to get involved in 2016 by attending one of our events. Please email Chares Stacey (cstacey@accerapharma.com), Kira Sheinerman (ksheinerman@diamirbio.com) or Jim Hendrix (jhendrix@alz.org) to be added to the membership list mailing list.

Mission of the AASCC

The mission of the AASCC is to advance Alzheimer’s disease research and innovation in start-up biotechnology, diagnostics, medical device and contract research organizations.

The AASCC works to achieve their mission by working in areas of common interest in a pre-competitive space to advance both the field of Alzheimer’s research and the member company’s goals. The AASCC member companies provide leadership and direction to the organization’s areas of focus that include but are not limited to: Collaborations, Recognition & Visibility and Knowledge and Information Sharing.

Schedule of Events for 2016

1. Alzheimer’s Disease Investment Panel @ BioTech Showcase 2016
   
   **Topic:** Alzheimer’s disease: has the tide turned?
   **Date:** Monday, January 11th 2016, 8:00–8:55 am
   **Venue:** Parc 55 San Francisco, 55 Cyril Magnin Street, San Francisco

Over the past 10 years, Alzheimer’s disease has seen an unprecedented level of failures in late stage clinical trials. This has, in part, been attributed to a focus on a narrow range of therapeutic targets, addressing the wrong stage of the disease, and inadequate selection of trial participants. This in turn has led to a systemic skepticism among the investors and in pharma with regards to Alzheimer’s disease. At the same time, public and governments awareness about the huge unmet clinical need in Alzheimer’s continues to increase. In addition, there is a new optimism in the field due to recent advances in the understanding of the disease and, hence, more targeted approaches to developing products. This session will question whether this interest is translating into increased interest in investment and M&A. Furthermore, the
Panelists will discuss what investors are looking for and how companies can best position themselves.

Confirmed Panelists:
Andrew Fein – Senior Biotechnology Analyst, HC Wainwright; Jim Hendrix – Director, Global Science Initiatives, Alzheimer's Association; Guy Seabrook – VP, Neuroscience Innovation, J&J Innovation. Moderator: Charles Stacey – Co-Chair of the AASCC and CEO, Accera


Members of the AASCC receive a $200 registration discount to attend or present at BioTechShowcase, please register by writing BTS2016 AASCC SUPPORTER DISCOUNT in the comments field when registering.

2. Webinar: What does pharma look for in evaluating companies as potential partners?
   Date: February 24 at 11 am ET / 8 am PT.
   Speaker: Declan Jones, Vice President, Neuroscience Lead, J & J Innovation Center
   https://alz-org.webex.com/alz-org/j.php?MTID=m96091f7887251176ebd3280199967df
   Meeting number: 745 862 515

3. Webinar: Success stories in Alzheimer’s Disease
   Date and Speaker/s: TBC

4. Webinar: Regulatory Affairs in AD- is the FDA cutting AD companies any slack?
   Date and Speaker/s: TBC

Networking Event Schedule

1. AAIC 2016, Toronto, Canada
   Date: July 22-23, 2016 (Date/time and venue TBC)
2. SfN 2016, San Diego, USA
   Date: November 12-16, 2016 (Date/time and venue TBC)
3. CTAD 2016, San Diego, USA
   Date: December 8-10, 2016 (Date/time and venue TBC)

Stay tuned for other events and updates.

We wish everyone wonderful holidays and happy, healthy and prosperous New Year!

Best wishes,

Charles Stacey and Kira Sheinerman
Co-chairs of the AASCC